We aimed to construct a prognostic gene signature based on TGF-β signaling-related genes for predicting clinical prognosis and immunotherapy responses of patients with clear cell renal cell carcinoma (ccRCC). This evidence concerns the gene TGFB1 and nonpapillary renal cell carcinoma.